138 related articles for article (PubMed ID: 3030390)
1. Immunoreactive prolyl hydroxylase in patients with primary and secondary myelofibrosis.
Wang JC; Wong C; Kao WW
Br J Haematol; 1987 Feb; 65(2):171-4. PubMed ID: 3030390
[TBL] [Abstract][Full Text] [Related]
2. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
[TBL] [Abstract][Full Text] [Related]
3. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
Arrago JP; Poirier O; Najean Y
Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactive prolyl hydroxylase protein and galactosylhydroxylysyl glucosyltransferase activity in breast tissues and sera of patients with primary breast cancer.
Bolarin DM
Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):493-502. PubMed ID: 6304825
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
Martyré MC
Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
[TBL] [Abstract][Full Text] [Related]
6. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD; Risteli L; Risteli J
Am J Hematol; 1986 Oct; 23(2):101-11. PubMed ID: 3752065
[TBL] [Abstract][Full Text] [Related]
7. Muramidase activity in leukemia and myeloproliferative disorders.
Skarin AT; Matsuo Y; Moloney WC
Oncology; 1973; 27(5):406-14. PubMed ID: 4515747
[No Abstract] [Full Text] [Related]
8. Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
Wang JC; Chen C; Dumlao T; Naik S; Chang T; Xiao YY; Sominsky I; Burton J
Leuk Lymphoma; 2008 Dec; 49(12):2321-7. PubMed ID: 19052980
[TBL] [Abstract][Full Text] [Related]
9. Serum procollagen III peptide in chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD
Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
[TBL] [Abstract][Full Text] [Related]
11. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
[TBL] [Abstract][Full Text] [Related]
12. [Bone marrow fibrosis in malignant hemopathies and cancers. Histological study of 2 786 biopsies (author's transl)].
Duhamel G; Stachowiak J
Sem Hop; 1981 Jan 18-25; 57(3-4):111-6. PubMed ID: 6261348
[TBL] [Abstract][Full Text] [Related]
13. Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.
Bolarin DM; Savolainen ER; Kivirikko KI
Int J Cancer; 1982 Apr; 29(4):401-5. PubMed ID: 6282764
[TBL] [Abstract][Full Text] [Related]
14. [Coexistence of myelofibrosis and collagen diseases].
Bistue R; Gallo de Sprazzato ME; Scognamillo CD; Porretta de Croceri L; Estevez MM; Guerra D
Medicina (B Aires); 1990; 50(3):248-50. PubMed ID: 2130212
[TBL] [Abstract][Full Text] [Related]
15. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
16. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
17. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.
Buhr T; Georgii A; Choritz H
Pathol Res Pract; 1993 Mar; 189(2):121-32. PubMed ID: 8321741
[TBL] [Abstract][Full Text] [Related]
18. Concomitant hydroxylation of proline and lysine residues in collagen using purified enzymes in vitro.
Turpeenniemi-Hujanen T; Myllylä R
Biochim Biophys Acta; 1984 Jul; 800(1):59-65. PubMed ID: 6331520
[TBL] [Abstract][Full Text] [Related]
19. [Hypocholesterolemia and other lipoprotein disorders in myelofibrosis].
Kiss A; Telek B; Rák K
Orv Hetil; 1994 Nov; 135(48):2643-6. PubMed ID: 7808738
[TBL] [Abstract][Full Text] [Related]
20. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
